metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced OC (mOC) - maintenance (M) 2
pancreatic ductal adenocarcinoma
PIK3CA-related overgrowth spectrum
prostate cancer (PC)

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab plus SoC
nivolumab based treatment
poly ADP-ribose polymerase (PARP) inhibitor
rucaparib

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs poly ADP-ribose polymerase (PARP) inhibitor
vs rucaparib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open